abstract: BACKGROUND: Intravesical treatment with @entity1138 ( @entity1139 ) leads to a complete response rate of around 40% in superficial @entity150 ( @entity8214 ). In order to determine in advance which @entity1 will fail to respond, we describe a study assessing the feasibility of applying the @entity855 assay to test the chemosensitivity of samples from @entity1 with this disease. MATERIALS AND METHODS: TURBT or biopsy samples were received from 27 @entity1 , 23 of which were suitable for the @entity855 assay (16 primary @entity5 and 7 recurrences). RESULTS: The success rate of the assay was 91%. There was a marked variation in the effect of @entity1139 between @entity1 with a > 50-fold range in LC50 values (drug concentration required to kill 50% of cells) from 2.99- > 150 microM with a median value of 22.4 microM. We were unable to determine any overall correlation between chemosensitivity and @entity5 stage or grade or the treatment status of the @entity1 in this small data set. @entity1262 status and @entity522 levels were assessed on these samples using immunohistochemistry but there did not appear to be any relationship between either of these parameters and @entity1139 resistance. Apoptotic counts and mitotic counts were also measured but, whilst these appeared to correlate with grade (p < 0.01), there was no overall significant relationship established with @entity1139 chemosensitivity. CONCLUSION: This study suggests that it is possible to use the @entity855 assay for chemosensitivity testing in TCCs. Despite a lack of overall correlation between ex vivo @entity1139 resistance and the conventional prognostic factors tested, further studies are warranted in a larger data set to test the ability of this technique to predict clinical outcome in this disease.

title: Ex vivo chemosensitivity to XXXX in @entity150 and its relationship with @entity1262 and apoptotic factors.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour']

entities_list: @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin C']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']

answer: @entity1138 :: (MESH:D016685,Chemical) :: ['mitomycin C']


abstract: BACKGROUND: Intravesical treatment with @entity1138 ( @entity1139 ) leads to a complete response rate of around 40% in superficial @entity150 ( @entity8214 ). In order to determine in advance which @entity1 will fail to respond, we describe a study assessing the feasibility of applying the @entity855 assay to test the chemosensitivity of samples from @entity1 with this disease. MATERIALS AND METHODS: TURBT or biopsy samples were received from 27 @entity1 , 23 of which were suitable for the @entity855 assay (16 primary @entity5 and 7 recurrences). RESULTS: The success rate of the assay was 91%. There was a marked variation in the effect of @entity1139 between @entity1 with a > 50-fold range in LC50 values (drug concentration required to kill 50% of cells) from 2.99- > 150 microM with a median value of 22.4 microM. We were unable to determine any overall correlation between chemosensitivity and @entity5 stage or grade or the treatment status of the @entity1 in this small data set. @entity1262 status and @entity522 levels were assessed on these samples using immunohistochemistry but there did not appear to be any relationship between either of these parameters and @entity1139 resistance. Apoptotic counts and mitotic counts were also measured but, whilst these appeared to correlate with grade (p < 0.01), there was no overall significant relationship established with @entity1139 chemosensitivity. CONCLUSION: This study suggests that it is possible to use the @entity855 assay for chemosensitivity testing in TCCs. Despite a lack of overall correlation between ex vivo @entity1139 resistance and the conventional prognostic factors tested, further studies are warranted in a larger data set to test the ability of this technique to predict clinical outcome in this disease.

title: Ex vivo chemosensitivity to @entity1138 in XXXX and its relationship with @entity1262 and apoptotic factors.

answer: @entity150 :: (MESH:D001749,Disease) :: ['bladder cancer']


abstract: BACKGROUND: Intravesical treatment with @entity1138 ( @entity1139 ) leads to a complete response rate of around 40% in superficial @entity150 ( @entity8214 ). In order to determine in advance which @entity1 will fail to respond, we describe a study assessing the feasibility of applying the @entity855 assay to test the chemosensitivity of samples from @entity1 with this disease. MATERIALS AND METHODS: TURBT or biopsy samples were received from 27 @entity1 , 23 of which were suitable for the @entity855 assay (16 primary @entity5 and 7 recurrences). RESULTS: The success rate of the assay was 91%. There was a marked variation in the effect of @entity1139 between @entity1 with a > 50-fold range in LC50 values (drug concentration required to kill 50% of cells) from 2.99- > 150 microM with a median value of 22.4 microM. We were unable to determine any overall correlation between chemosensitivity and @entity5 stage or grade or the treatment status of the @entity1 in this small data set. @entity1262 status and @entity522 levels were assessed on these samples using immunohistochemistry but there did not appear to be any relationship between either of these parameters and @entity1139 resistance. Apoptotic counts and mitotic counts were also measured but, whilst these appeared to correlate with grade (p < 0.01), there was no overall significant relationship established with @entity1139 chemosensitivity. CONCLUSION: This study suggests that it is possible to use the @entity855 assay for chemosensitivity testing in TCCs. Despite a lack of overall correlation between ex vivo @entity1139 resistance and the conventional prognostic factors tested, further studies are warranted in a larger data set to test the ability of this technique to predict clinical outcome in this disease.

title: Ex vivo chemosensitivity to @entity1138 in @entity150 and its relationship with XXXX and apoptotic factors.

answer: @entity1262 :: (5243,Gene) :: ['P-glycoprotein']


abstract: We report six @entity1 with @entity66 in whom @entity625 was prominent at diagnosis and who improved with dietary therapy. Joint @entity158 preceded diagnosis by up to three years in five @entity1 and 15 years in one @entity1 . Joints most commonly involved were lumbar spine, hips, and knees (four cases). In three cases there were no bowel symptoms. All were seronegative. X-rays were abnormal in two cases. HLA-type A1, B8, @entity4106 was present in five and B27 in two @entity1 . Circulating immune complexes showed no consistent pattern before or after treatment. @entity66 was diagnosed in all @entity1 by jejunal biopsy, and joint symptoms in all responded to a gluten-free diet. Gluten challenge (for up to three weeks) failed to provoke @entity625 in three @entity1 tested. In a separate study of 160 treated coeliac @entity1 attending regular follow up no @entity625 attributable to @entity66 and no @entity1691 was identified, though in a control group of 100 @entity1 with @entity30 the expected incidence of seronegative @entity625 (23%) and @entity1691 (5%) was found (p less than 0.01). @entity625 appears to be a rare manifestation of @entity66 . This relationship may provide important clues to the role of gastrointestinal antigens in @entity627 .

title: XXXX and @entity66 .

entities_list: @entity627 :: ('MESH:D012216', 'Disease') :: ['rheumatic diseases']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Coeliac disease', 'coeliac disease']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['Arthritis', 'arthritis', 'polyarthritis']

entities_list: @entity1691 :: ('MESH:D013167', 'Disease') :: ['ankylosing spondylitis']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]

answer: @entity625 :: (MESH:D001168,Disease) :: ['Arthritis']


abstract: We report six @entity1 with @entity66 in whom @entity625 was prominent at diagnosis and who improved with dietary therapy. Joint @entity158 preceded diagnosis by up to three years in five @entity1 and 15 years in one @entity1 . Joints most commonly involved were lumbar spine, hips, and knees (four cases). In three cases there were no bowel symptoms. All were seronegative. X-rays were abnormal in two cases. HLA-type A1, B8, @entity4106 was present in five and B27 in two @entity1 . Circulating immune complexes showed no consistent pattern before or after treatment. @entity66 was diagnosed in all @entity1 by jejunal biopsy, and joint symptoms in all responded to a gluten-free diet. Gluten challenge (for up to three weeks) failed to provoke @entity625 in three @entity1 tested. In a separate study of 160 treated coeliac @entity1 attending regular follow up no @entity625 attributable to @entity66 and no @entity1691 was identified, though in a control group of 100 @entity1 with @entity30 the expected incidence of seronegative @entity625 (23%) and @entity1691 (5%) was found (p less than 0.01). @entity625 appears to be a rare manifestation of @entity66 . This relationship may provide important clues to the role of gastrointestinal antigens in @entity627 .

title: @entity625 and XXXX .

answer: @entity66 :: (MESH:D004194,Disease) :: ['coeliac disease']


abstract: @entity4240 is an @entity74 of squamous epithelium that results in @entity3986 of the skin after minor @entity130 . Although severe @entity2318 of the skin is the most common and obvious complication of the disease, esophageal @entity2318 with formation of long strictures may also develop. In two affected siblings, such esophageal strictures occurred and progressed in severity to degrees necessitating esophageal replacement. Each received a preoperative period of total parenteral nutrition, which was continued into the postoperative period. In one, an isoperistaltic segment of right colon was placed substernally in a single stage procedure. In the other, a substernal reversed gastric tube was constructed, also in a single stage. This latter procedure was shorter and technically simpler than the colon interposition. The early postoperative courses in both were complicated by cervical @entity834 , which sealed spontaneously during a period of parenteral nutrition and @entity3685 . Both subsequently developed cervical @entity850 . These were successfully managed by dilatations, and both @entity1 are now tolerating a solid diet. Neither @entity1 experienced problems from endotracheal intubation. Epithelial loss occurred in the skin adjacent to the surgical incision but healed quickly with topical @entity1217 therapy. This report confirms previous reports that esophageal replacement is well tolerated by @entity1 with @entity2640 and suggests that the reversed gastric tube technique, not previously reported used for this disease, may be preferable to colon esophagoplasty.

title: Esophageal replacement in two siblings with XXXX .

entities_list: @entity834 :: ('MESH:D057868', 'Disease') :: ['anastomotic leaks']

entities_list: @entity3986 :: ('MESH:D009136', 'Disease') :: ['dystrophic scarring']

entities_list: @entity4240 :: ('MESH:D016108', 'Disease') :: ['Dystrophic epidermolysis bullosa']

entities_list: @entity2640 :: ('MESH:D004820', 'Disease') :: ['epidermolysis bullosa']

entities_list: @entity3685 :: ('MESH:D019959', 'Disease') :: ['gastrostomy feedings']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['inherited disorder']

entities_list: @entity1217 :: ('MESH:D012837', 'Chemical') :: ['silver sulfadiazine']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['anastomotic strictures']

answer: @entity2640 :: (MESH:D004820,Disease) :: ['epidermolysis bullosa']


abstract: @entity460 and @entity1391 metabolism abnormalities are frequent in @entity1582 @entity1 and the role of @entity8 in such ionic perturbations may have been overlooked. The authors herein report the complete primary structure of a Bence Jones Vkappal light chain responsible for @entity8 with increased @entity14104 . Plasma and serum biochemical evaluations indicated a proximal tubular dysfunction mainly manifested as @entity34004 and @entity1391 loss. The study of a kidney biopsy showed @entity8 with numerous @entity1582 casts and peculiar features of the proximal tubular cells, which carried numerous phagolysosomal inclusions with occasional crystalline periodic striation. The nephrotoxic light chain primary structure was deduced from the bone marrow monoclonal plasma cells RNA. The kappal sequence was highly homologous to kappa chains previously characterized in @entity1 with @entity4434 . It was related to the Vkappal subgroup and was composed of a variable segment encoded by the O8/O18 germline gene rearranged to Jkappa4. The primary sequence presented unusual features restricted to the variable region, including substitutions of residues 28 and 31 in the complementary determining region 1 (CDR1) by @entity1522 of different charge. An unusual conformation of the kappal domain, likely resulting from somatic hypermutation, could alter the catabolism of the protein after its internalization and result in the tubular cell dysfunction. Comparison with @entity4434 studies suggests that Vkappal Bence Jones proteins may damage proximal tubular cells to an extent varying according to light chain (LC) sequence and structure, either leading to crystal formation and @entity4434 or inducing partial inhibition of proximal tubule function.

title: A monoclonal V kappa l light chain responsible for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal lesions', 'interstitial and tubular lesions', 'myeloma-associated proximal tubulopathy']

entities_list: @entity14104 :: ('MESH:D007015', 'Disease') :: ['phosphaturia']

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity34004 :: ('MESH:D000141', 'Disease') :: ['tubular acidosis']

entities_list: @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['Calcium']

entities_list: @entity4434 :: ('MESH:D005198', 'Disease') :: ['Fanconi syndrome']

answer: @entity8 :: (MESH:D007674,Disease) :: ['incomplete proximal tubulopathy']


abstract: The purpose of the study reported here was to further investigate a new method of estimating inbreeding in large, relatively isolated populations over historic times, as reported by Pattison (1999, 2001). The method is based on modeling the genealogical "paradox" and produces values of Pearl's coefficients of inbreeding as a function of time for any given population curve. In particular, this study demonstrates that the new method of estimating inbreeding may be used to examine the effect of unusual features in population curves on levels of inbreeding in that population. As an example, the medieval population "bump" that spans the 13th and 14th centuries in the population of Britain, which terminated abruptly with the outbreak of @entity1407 in 1348 @entity195 , is examined. It is first assumed that the whole population was the adult (breeding) population, corresponding to minimum inbreeding. For this case it is found that, for distant generations, about 90% of the whole population occurs in any present-day British pedigree. This value compares favorably with the values of 85% and 80% reported by Wachter (1980) and Derrida et al. (1999, 2000), respectively. The population bump causes the curves for Pearl's coefficient, for minimum inbreeding, to have a plateau of about 96% over the period from about 1220 @entity195 to 1380 @entity195 . The effect of introducing a single known estimate of inbreeding into the model is to produce a more realistic situation where the adult (breeding) population is considerably less than the whole population. It is found that the maximum number of different ancestors in any generation, in the average British pedigree, is about 22900 individuals and occurs about 1220 @entity195 . More importantly, and possibly contrary to expectation, it is now found that the population bump had virtually no effect on the level of inbreeding.

title: Effect of the XXXX on inbreeding in 14th century Britain.

entities_list: @entity1407 :: ('MESH:D010930', 'Disease') :: ['bubonic plague']

answer: @entity1407 :: (MESH:D010930,Disease) :: ['bubonic plague epidemic']


abstract: BACKGROUND: To summarize the preliminary experience on Iressa for refractory @entity1149 ( @entity1149 ). METHODS: Fifty-five @entity1 with @entity1149 , who failed after surgery, radiotherapy, chemotherapy or combination of the above modalities, were registered in this clinical trail. Prior to Iressa, 50 @entity1 were in stage IV, and 5 in stage III. Iressa was administered orally at 250 mg, once a day until @entity5 progressed or severe @entity137 occured, which made @entity1 intolerable. The median time for administration of Iressa was 4 months. RESULTS: The @entity137 of Iressa was tolerable with 47% of @entity137 ( @entity1910 ) and 2%-7% of @entity294 , @entity390 , @entity9645 and @entity1665 . Overall response rate was 20%. Different sites of distant metastases responded to Iressa in different ways with higher response rate for pulmonary disseminations. One quarter of @entity1 felt improvement of their symptoms over 2 weeks. Median survival time for entire group was 5 months (1-17 months). Median @entity1054 ( @entity1054 ) was 3.6 months. Survival at 6 months was 67%. Prognostic predictor, which could imply the outcome, was @entity137 with higher response rate and longer survival time ( P < 0.05), and no relationship with sex, histological types of @entity1149 and distant @entity3 had been found. CONCLUSIONS: Iressa could be tolerated by refractory @entity1149 @entity1 with acceptable side-effects, and have palliative effects.

title: [Iressa for refractory XXXX : A preliminary report].

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'skin toxicity']

entities_list: @entity9645 :: ('MESH:D019226', 'Disease') :: ['orally mucosal ulceration']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'time to progression']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: BACKGROUND: @entity170 ( @entity170 ) is a metabolic bone illness that may complicate @entity1593 ( @entity1593 ). It can lead to devastating consequences because of low bone mass and @entity174 . PURPOSE: To study the @entity170 prevalence in a group of Brazilian @entity1 with @entity1593 and the value of a @entity1593 ( @entity1593 ). METHODS: Retrospective study of celiac female @entity1 from a single University Center followed with bone densitometries. Results from densitometry made at first visit were compared with a second study after a median time of 5 years. During this period, @entity1 were submitted to a @entity1593 according to orientations from special program training. @entity460 and @entity560 were prescribed to those @entity1 who did not reach the minimal daily requirement through diet. RESULTS: Forty-one celiac female @entity1 , mean age 46.1    14.8 years, were included. The prevalence of @entity2331 at first visit was 56.1% and that of @entity170 29.2%. @entity170 was associated with longer disease duration (p = 0.01). The second densitometry was performed in a median time of 5 years (range 1 to 13 years) and disclosed 58.9% @entity2331 and 28.2% @entity170 . The @entity1593 improved bone mass, mainly at (of) spine (comparison of T score with p = 0.03 and of bone mass in g/cm2 with p = 0.02), but it was not sufficient to reduce the number of @entity6092 (p = 0.9) and @entity3604 @entity1 (p = 0.4). During the follow up period 25% of @entity3604 @entity1 developed low impact @entity174 . CONCLUSION: Bone health is notably impaired at baseline in @entity1593 @entity1 , especially in those with a diagnostic delay. A @entity1593 modestly improved bone mass density with low impact @entity174 occurring in one third of @entity1 during the follow up period.

title: Impact of a gluten-free diet on bone mineral density in celiac XXXX .

entities_list: @entity3604 :: ('MESH:D058866', 'Disease') :: ['osteoporotic']

entities_list: @entity1593 :: ('MESH:D002446', 'Disease') :: ['celiac disease', 'gluten free diet', 'GFD', 'CD']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fragility fractures']

entities_list: @entity170 :: ('MESH:D010024', 'Disease') :: ['Osteoporosis', 'OP', 'osteoporosis']

entities_list: @entity2331 :: ('MESH:D001851', 'Disease') :: ['osteopenia']

entities_list: @entity6092 :: ('MESH:C567172', 'Disease') :: ['osteopenic']

entities_list: @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: Infusion of a source of endothelial progenitor cells (EPC) into the @entity63 myocardium is emerging as a promising therapy for @entity63 , probably mediated by the formation of new blood vessels. Studies have shown that while the procedure is safe and feasible, efficacy results are contentious. The investigators hypothesized that the infusion of a combination cell product consisting of a source of EPC and mesenchymal stem cells (MSC) is safe and promotes the formation of more stable and mature blood vessels resulting in improved clinical outcomes. METHODS: Ten @entity1 with stable @entity951 (class III to IV) on maximal medical therapy were included. All @entity1 had >=  70% stenosis in at least one coronary artery, and none was considered a candidate for percutaneous coronary intervention or coronary artery bypass graft. End points were feasibility and safety of intracoronary infusion of the combination cell product and assessment of @entity741 , left ventricular ejection fraction (LVEF), and quality of life at 6 months postinfusion. RESULTS: Six months after cell infusion there were no adverse clinical events. Functional cardiac evaluation during the same period showed significant improvements in LVEF (average increase: 11%, P = .02) and @entity741 (average decrease: 1.8 fold, P = .02). Additionally, all @entity1 described significant improvements in quality of life. CONCLUSIONS: Despite the inherent limitations associated with a Phase I clinical trial, this study demonstrates that the intracoronary infusion of the combination cell product is feasible and safe and also insinuates that this form of therapy may be beneficial.

title: Combination stem cell therapy for the treatment of medically refractory XXXX : a Phase I study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity951 :: ('MESH:D000787', 'Disease') :: ['angina pectoris']

entities_list: @entity741 :: ('MESH:D017202', 'Disease') :: ['myocardial ischemia']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic', 'coronary ischemia']

answer: @entity63 :: (MESH:D007511,Disease) :: ['coronary ischemia']


abstract: BACKGROUND: To evaluate the efficacy and safety of @entity1205 in combination with @entity3003 as first-line treatment of @entity1 with inoperable, locally advanced or metastatic @entity1149 ( @entity1149 ). @entity1 AND METHODS: Chemotherapy-naive @entity1 with stage IIIB and IV @entity1149 , age < 75 years, performance status (WHO) 0-2, were enrolled onto the study. @entity1205 was given at a dose of 100 mg/m2 over an 1-hour i.v. infusion. @entity3003 dosed to an area under the time-concentration curve (AUC) of 6 mg/ml.minute, using the Calvert's formula, was administered over a 30-minute i.v. infusion. The regimen was repeated every 3 weeks. RESULTS: Thirty-eight @entity1 received a total of 155 chemotherapy cycles (median 4 cycles/ @entity1 ). All @entity1 were assessable for @entity137 and 34 for response. There was one (2.6%) complete and nine (23.7%) partial responses; in an intention-to-treat analysis the overall response rate was 26.6% (95% CI: 12.3%-40.3%). The median duration of response was 7 months (range: 3-29), the median time to @entity5 progression 7 months (range: 3.5-31), and the median overall survival 9 months (range: 0.5-31.5). The probability for 1-year survival was 44%. Grade 3-4 @entity1398 was the main hematological @entity137 of the regimen occurring in 19 (50%) @entity1 . Four (10.5%) @entity1398 episodes were complicated with fever but there was no septic death. Non-hematological @entity137 was generally mild. CONCLUSION: These results indicate that the @entity1205 - @entity3003 combination is a relatively active and well-tolerated front-line regimen for the treatment of @entity1 with advanced or metastatic @entity1149 .

title: A multicenter phase II study of @entity1205 and @entity3003 combination as front-line treatment in advanced XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'neutropenic']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel', 'Docetaxel']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: BACKGROUND: To evaluate the efficacy and safety of @entity1205 in combination with @entity3003 as first-line treatment of @entity1 with inoperable, locally advanced or metastatic @entity1149 ( @entity1149 ). @entity1 AND METHODS: Chemotherapy-naive @entity1 with stage IIIB and IV @entity1149 , age < 75 years, performance status (WHO) 0-2, were enrolled onto the study. @entity1205 was given at a dose of 100 mg/m2 over an 1-hour i.v. infusion. @entity3003 dosed to an area under the time-concentration curve (AUC) of 6 mg/ml.minute, using the Calvert's formula, was administered over a 30-minute i.v. infusion. The regimen was repeated every 3 weeks. RESULTS: Thirty-eight @entity1 received a total of 155 chemotherapy cycles (median 4 cycles/ @entity1 ). All @entity1 were assessable for @entity137 and 34 for response. There was one (2.6%) complete and nine (23.7%) partial responses; in an intention-to-treat analysis the overall response rate was 26.6% (95% CI: 12.3%-40.3%). The median duration of response was 7 months (range: 3-29), the median time to @entity5 progression 7 months (range: 3.5-31), and the median overall survival 9 months (range: 0.5-31.5). The probability for 1-year survival was 44%. Grade 3-4 @entity1398 was the main hematological @entity137 of the regimen occurring in 19 (50%) @entity1 . Four (10.5%) @entity1398 episodes were complicated with fever but there was no septic death. Non-hematological @entity137 was generally mild. CONCLUSION: These results indicate that the @entity1205 - @entity3003 combination is a relatively active and well-tolerated front-line regimen for the treatment of @entity1 with advanced or metastatic @entity1149 .

title: A multicenter phase II study of @entity1205 and XXXX combination as front-line treatment in advanced @entity1149 .

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

answer: @entity3003 :: (MESH:D016190,Chemical) :: ['carboplatin']


abstract: BACKGROUND: To evaluate the efficacy and safety of @entity1205 in combination with @entity3003 as first-line treatment of @entity1 with inoperable, locally advanced or metastatic @entity1149 ( @entity1149 ). @entity1 AND METHODS: Chemotherapy-naive @entity1 with stage IIIB and IV @entity1149 , age < 75 years, performance status (WHO) 0-2, were enrolled onto the study. @entity1205 was given at a dose of 100 mg/m2 over an 1-hour i.v. infusion. @entity3003 dosed to an area under the time-concentration curve (AUC) of 6 mg/ml.minute, using the Calvert's formula, was administered over a 30-minute i.v. infusion. The regimen was repeated every 3 weeks. RESULTS: Thirty-eight @entity1 received a total of 155 chemotherapy cycles (median 4 cycles/ @entity1 ). All @entity1 were assessable for @entity137 and 34 for response. There was one (2.6%) complete and nine (23.7%) partial responses; in an intention-to-treat analysis the overall response rate was 26.6% (95% CI: 12.3%-40.3%). The median duration of response was 7 months (range: 3-29), the median time to @entity5 progression 7 months (range: 3.5-31), and the median overall survival 9 months (range: 0.5-31.5). The probability for 1-year survival was 44%. Grade 3-4 @entity1398 was the main hematological @entity137 of the regimen occurring in 19 (50%) @entity1 . Four (10.5%) @entity1398 episodes were complicated with fever but there was no septic death. Non-hematological @entity137 was generally mild. CONCLUSION: These results indicate that the @entity1205 - @entity3003 combination is a relatively active and well-tolerated front-line regimen for the treatment of @entity1 with advanced or metastatic @entity1149 .

title: A multicenter phase II study of XXXX and @entity3003 combination as front-line treatment in advanced @entity1149 .

answer: @entity1205 :: (MESH:C067311,Chemical) :: ['docetaxel']


abstract: BACKGROUND: @entity1 with @entity1187 ( @entity1187 ) frequently present with typical @entity662 ; however a considerable proportion may present with atypical symptoms. OBJECTIVE: The purpose of this study was to evaluate the prognostic value of different presenting symptoms in @entity1187 @entity1 . METHODS: Over a 5-month period in 2007, 6704 consecutive @entity1 presenting with @entity1187 were enrolled and categorized into three groups according to their presenting symptom (typical @entity662 , atypical @entity662 , and @entity1353 ). Data were collected from a prospective, multicenter, multinational, observational study from 6 countries. The baseline characteristics, therapy, and in-hospital outcomes were analyzed and compared in the three groups. RESULTS: In comparison to typical @entity662 , @entity1 with @entity158 or @entity1353 were older and had more cardiovascular risk factors. These two groups were significantly less likely to receive evidence-based therapy and coronary angiography and suffered worse in-hospital outcomes. The mortality rates were 3%, 2.5%, and 6% in @entity1 presenting with typical, atypical @entity662 , and @entity1353 , respectively. After adjustment for confounders, the absence of typical @entity662 was associated with higher mortality rate (odds ratio 2.0, 95% confidence intervals 1.29-2.75). CONCLUSIONS: Across @entity1187 , @entity1 presenting without @entity662 were frequently underestimated, less well treated with evidence-based therapy, and had worse in-hospital outcomes. Clinical presentation of @entity1187 may provide additional prognostic impact particularly in high-risk populations.

title: Atypical presentation of XXXX : a significant independent predictor of in-hospital mortality.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['atypical pain']

answer: @entity1187 :: (MESH:D054058,Disease) :: ['acute coronary syndrome']


abstract: Perturbations in the normal sequence of ventricular activation can create regions of early and late activation, leading to @entity2472 and areas of dyskinesis. Dyskinesis occurs across the left ventricular (LV) wall, and its presence may have important consequences on cardiac structure and function in normal and failing hearts. Acutely, dyskinesis can trigger @entity32 and, in the long term (6 wk and above), leads to LV remodeling. The mechanisms that trigger these changes are unknown. To gain further insight, we used a @entity235 model to evaluate transumural changes in myocardial function and @entity32 induced by epicardial LV pacing. The results indicate that 4 h of LV suprathreshold pacing resulted in a 30% local loss of endocardial thickening. Assessment of neutrophil infiltration showed a significant approximately fivefold increase in @entity20402 activity in the epicardium versus the midwall/endocardium. @entity11799 activity increased    2 fold in the epicardium and ROS generation increased    2.5-fold compared with the midwall/endocardium. To determine the effects that electrical current alone has on these end points, a group of animals was subjected to subthreshold pacing. Significant increases were observed only in epicardial @entity20402 levels. Thus, the results indicate that transmural dyskinesis induced by suprathreshold epicardial LV activation triggers a localized epicardial inflammatory response, whereas subthreshold stimulation appears to solely induce the trapping of leucocytes. Suprathreshold pacing also induces a loss of endocardial function. These results may have important implications as to the nature of the mechanisms that trigger the inflammatory response and possibly long-term remodeling in the setting of dysynchrony.

title: Ventricular pacing-induced loss of contractile function and development of XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity11799 :: ('403885(Tax:9615)', 'Gene') :: ['Matrix metalloproteinase-9']

entities_list: @entity2472 :: ('MESH:C536214', 'Disease') :: ['dysynchronous contraction']

answer: @entity32 :: (MESH:D007249,Disease) :: ['epicardial inflammation']


abstract: BACKGROUND: Torsion of the ovary is a rare but serious cause of gynecologic surgical emergency. Specific laboratory markers that support the preoperative diagnosis of @entity43 are not currently available in the clinical routine. The aim of this study was to investigate the diagnostic value of plasma D-dimer level as an early indicator of @entity43 in an experimental @entity35 @entity43 model. METHODS: Sixteen female adult @entity35 were used for this controlled experimental study. Eight @entity35 in the sham operation group (Group I) underwent a surgical procedure similar to Group II but the ovary was not occluded. In Group II (eight @entity35 ), a torsion model was created by using atraumatic vascular clips just above and below the right ovary for a 2-h period of @entity63 . Right ovaries were surgically removed at the end of the procedure in each group. Blood was sampled before and after operation to assess plasma D-dimer levels. The main outcome measure was ovarian histopathologic findings scores and plasma D-dimer levels. RESULTS: There was no significant difference in pre-operative plasma D-dimer levels (0.5963    0.2047 mg/l in Group I, 0.6344    0.1348 mg/l in Group II, P = 0.815, Mann-Whitney U-test). However, mean plasma D-dimer value for Group II was significantly higher than that in the control group (1.2267    0.3099 versus 0.6213    0.2346 mg/l, respectively, Mann-Whitney U-test, P < 0.001), following 2 h of @entity43 . Ovarian tissue damage scores were also statistically significantly different among groups. CONCLUSIONS: If the observations made in a @entity35 model are extended to @entity1 , plasma D-dimer measurement may be a valuable parameter in the early diagnosis of @entity43 .

title: Acute increase in plasma D-dimer level in XXXX : an experimental study.

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian torsion']

entities_list: @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats', 'rats']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian torsion']


abstract: OBJECTIVES: @entity1 can fulfil clinical criteria for remission, yet still have evidence of @entity603 detectable clinically and by ultrasound, and this is associated with structural damage. Stricter remission criteria may more accurately reflect true remission (no @entity603 ). This hypothesis was examined by studying @entity1 using more stringent thresholds for clinical remission and determining their levels of ultrasound @entity603 . METHODS: @entity309 @entity1 with a disease activity score in 28 joints (DAS28)  <=2.6 for at least 6 months were classified using standard and more stringent DAS28 and simplified disease activity index (SDAI) remission thresholds and the corresponding clinical and ultrasound imaging measures of @entity603 recorded. RESULTS: 128 @entity1 (all DAS28 <2.6, median DAS28 1.70) receiving either disease-modifying antirheumatic drugs alone (n=66) or with a @entity5 @entity39 factor blocker (n=62) were recruited. Of the 640 imaged joints, 5% had moderate or severe power Doppler (PD) activity, 8% were clinically swollen and 1% tender. In @entity1 fulfilling DAS28, American College of Rheumatology or SDAI remission criteria, moderate or severe PD activity was present in 21%, 15% and 19%, respectively. More stringent DAS28 and SDAI criteria reduced the mean number of swollen and @entity2720 (p<0.001) but not the percentage of @entity1 with PD activity: 32 @entity1 had a DAS28 <1.17 but eight (25%) had significant PD activity. CONCLUSION: Using more stringent remission criteria resulted in reduced signs and symptoms of @entity32 , but the percentage of joints with PD activity was not reduced, even in those without signs or symptoms. These data suggest that clinical criteria are sufficiently insensitive to detect low but clinically relevant levels of @entity32 accurately.

title: Should imaging be a component of XXXX remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments.

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity603 :: ('MESH:D013585', 'Disease') :: ['synovitis']

entities_list: @entity2720 :: ('MESH:D007592', 'Disease') :: ['tender joints']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['Rheumatoid arthritis']

answer: @entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']


abstract: @entity1735 -peptide hydrogels have been developed in our laboratory as new synthetic extracellular matrices for regenerative medicine applications. In this work, we have expanded on our previously reported system and applied copolymerization of @entity462 ( @entity2569 ) and @entity72322 (VS)-functionalized @entity1735 -peptide polymers via Michael-type addition for encapsulation and 3D culture of cells. Specifically, our aims were to (1) develop a novel hydrogel platform, which could be applied for encapsulating and culturing mesenchymal stem cells (MSCs) in a 3D environment, (2) characterize the tunable properties of the hydrogel, specifically, degradation, mechanical, and gel network properties, and (3) determine the biocompatibility of the @entity1735 -peptide hydrogel material with MSCs. Hydrogel mechanical properties were tunable by varying the VS: @entity2569 ratio (= 0.5, 1, or 2) as well as the pH (6, 7, or 8) of the cross-linking components. Stiffer gels were formed at VS: @entity2569 = 1 and pH 6 or 7. Gels formed at pH 8 or with excess @entity2569 (VS: @entity2569 = 0.5) or VS (VS: @entity2569 = 2) were significantly softer. @entity8487 and VS: @entity2569 ratio also had an effect on the degradation behavior of the VS: @entity2569 gels, with higher cross-linking pH resulting in an accelerated loss of mass. On the basis of environmental scanning electron microscopy (ESEM) analysis and fluorescence microscopy, all hydrogels appeared to exhibit porous gel networks. MSCs cultured in monolayer and exposed to soluble @entity2569 or VS copolymers (0.1-5 mg/mL) did not exhibit measurable @entity137 . In addition, MSCs were cultured in 3D for up to 14 days in vitro without deleterious effects on cell viability. In summary, we have established and characterized a tunable 3D @entity1735 -peptide hybrid copolymer hydrogel platform for culturing MSCs. Future studies will focus on utilizing the hydrogel system for controlling the differentiation of MSCs.

title: Biodegradable and biocompatible synthetic XXXX -Peptide hydrogels for three-dimensional stem cell culture.

entities_list: @entity8487 :: ('MESH:D010677', 'Disease') :: ['Cross-linking pH']

entities_list: @entity462 :: ('MESH:D003545', 'Chemical') :: ['cysteine']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['Saccharide', 'saccharide']

entities_list: @entity72322 :: ('MESH:C009873', 'Chemical') :: ['vinyl sulfone']

answer: @entity1735 :: (CHEBI:16646,Chemical) :: ['saccharide']


abstract: Cold-induced changes of gene expression and metabolism are critical for plants to survive freezing. Largely by changing gene expression, exposure to a period of non-freezing low temperatures increases plant tolerance to freezing-a phenomenon known as cold acclimation. Cold also induces rapid metabolic changes, which provide instant protection before temperature drops below freezing point. The molecular mechanisms for such rapid metabolic responses to cold remain largely unknown. Here, we use two-dimensional difference gel electrophoresis (2-D DIGE) analysis of sub-cellular fractions of @entity958 proteome coupled with spot identification by tandem mass spectrometry to identify early cold-responsive proteins in @entity958 . These proteins include four enzymes involved in starch degradation, three HSP100 proteins, several proteins in the @entity6626 cycle, and @entity969 metabolism. Upon cold treatment, the @entity25409 ( @entity25409 ), a cytosolic transglucosidase metabolizing maltose to @entity413 , increased rapidly in the centrifugation pellet fraction and decreased in the soluble fraction. Consistent with cold-induced inactivation of @entity25409 enzymatic activity, the @entity25409 mutant showed increased freezing tolerance without affecting the C-repeat binding transcription factor (CBF) transcriptional pathway. These results support a model that cold-induced inactivation of @entity25409 leads to rapid accumulation of @entity7969 , which is a cold-induced compatible solute that protects cells from freezing damage. This study provides evidence for a key role of rapid post-translational regulation of @entity1735 metabolic enzymes in plant protection against sudden temperature drop.

title: Proteomics analysis reveals post-translational mechanisms for cold-induced metabolic changes in XXXX .

entities_list: @entity958 :: ('3702', 'Species') :: ['Arabidopsis thaliana', 'Arabidopsis']

entities_list: @entity25409 :: ('818682(Tax:3702)', 'Gene') :: ['Disproportionating Enzyme 2', 'dpe2', 'DPE2']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

entities_list: @entity6626 :: ('CHEBI:27093', 'Chemical') :: ['tricarboxylic acid']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity958 :: (3702,Species) :: ['Arabidopsis']


abstract: A three-year-old male @entity1 was brought to our clinic by his family with the complaint of a non-healing wound with discharge on his forehead and the nasal region. He had a history of a fall one-year ago. The @entity1 had recurrent complaints of @entity4 and @entity450 following this @entity130 . He had undergone an operation with the pre-diagnosis of foreign body in soft tissue six months ago. However, no foreign body had been detected and the inflamed tissue had been excised and closed again. The @entity4 and purulent discharge in the region between nose and eye continued after this surgery. The @entity1 underwent an operation and a circular defect 0.5 cm in diameter was detected on the dorsum of the nasal bone and a @entity292 tract was found to have developed between this defect and the skin between the nose and the eye. A subcutaneous @entity542 without skin tissue was removed including the periosteum from the left part of forehead after excision of the @entity292 tract. The flap was transferred to the nasal dorsum and the component of the @entity542 including the periosteum was used for reconstruction of the nasal mucosa. The wound healed without any problems and no @entity292 or @entity281 developed again during the six-month follow-up.

title: A rare case of XXXX : nasocutaneous @entity292 .

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['swelling']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['forehead flap']

entities_list: @entity450 :: ('MESH:D006940', 'Disease') :: ['hyperemia']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity292 :: (MESH:D005402,Disease) :: ['fistula']


abstract: A three-year-old male @entity1 was brought to our clinic by his family with the complaint of a non-healing wound with discharge on his forehead and the nasal region. He had a history of a fall one-year ago. The @entity1 had recurrent complaints of @entity4 and @entity450 following this @entity130 . He had undergone an operation with the pre-diagnosis of foreign body in soft tissue six months ago. However, no foreign body had been detected and the inflamed tissue had been excised and closed again. The @entity4 and purulent discharge in the region between nose and eye continued after this surgery. The @entity1 underwent an operation and a circular defect 0.5 cm in diameter was detected on the dorsum of the nasal bone and a @entity292 tract was found to have developed between this defect and the skin between the nose and the eye. A subcutaneous @entity542 without skin tissue was removed including the periosteum from the left part of forehead after excision of the @entity292 tract. The flap was transferred to the nasal dorsum and the component of the @entity542 including the periosteum was used for reconstruction of the nasal mucosa. The wound healed without any problems and no @entity292 or @entity281 developed again during the six-month follow-up.

title: A rare case of @entity292 : nasocutaneous XXXX .

answer: @entity292 :: (MESH:D005402,Disease) :: ['fistula']


abstract: The increased susceptibility of severely injured @entity1 to @entity281 and @entity204 from @entity295 has been attributed to abnormalities in cell-mediated immunity. The authors therefore assessed the relative number of peripheral blood T helper cells and T suppressor/cytotoxic cells and total T lymphocytes identified by the monoclonal antibodies (McA) OKT4, OKT8, and OKT3, respectively, in 25 @entity1 with burns from 5 to 85% total body surface area (TBSA) (mean: 40%) and 21 @entity1 with nonthermal injuries (mean Injury Severity Score (ISS): 21.4). @entity1 were compared to 21 healthy controls. Cells reacting with the @entity9623 were detected by flow cytometry, which enabled the examination of a population of cells the size of T lymphocytes, excluding larger contaminating cells that might bind the McA. @entity1 with burns of 30% TBSA or greater had a significant reduction (p less than or equal to 0.05) in @entity19 + cells up to 50 days post-burn. Both septic and nonseptic burn @entity1 had reduced numbers of @entity19 + cells, as did @entity1 after nonthermal injury, suggesting that this reduction was due to the injury itself. @entity1 with smaller burns (less than 30% TBSA) as a group did not have reduced @entity19 + cells, whereas those with larger burns showed significant reductions in @entity19 + cells (P less than or equal to 0.05) at 0 to 5, 6 to 10, 11 to 20, 21 to 30, and 41 to 50 days post-burn. Seven burn @entity1 who became septic 10 days post-burn or later had significantly lower @entity19 + cells within 10 days of injury (mean: 33.75% +/- 7.4 SEM) than 10 @entity1 who remained free of @entity295 (mean: 42.2% +/- 5.4, p = 0.004). @entity1 with uncomplicated nonthermal injuries failed to show any significant reduction in @entity19 + cells. Following @entity130 , a reduction in @entity19 + cells was observed up to 10 days in @entity1 with burns less than 30% TBSA, and up to 20 days in @entity1 with larger burns. In both groups, at no time were increased @entity19 + cells found to correlate with clinical events. In @entity1 with nonthermal injury, @entity19 + cells generally remained near the normal range.

title: Changes in T lymphocyte subsets following injury. Assessment by flow cytometry and relationship to XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['thermal injury']

answer: @entity295 :: (MESH:D018805,Disease) :: ['sepsis']


abstract: Forearm vascular responses to intra-arterial infusions of endothelium-dependent and -independent vasodilators have been thoroughly characterized in @entity1 . While the forearm is a well-established experimental model for studying @entity1 vascular function, it is of limited consequence to systemic cardiovascular control owing to its small muscle mass and blood flow requirements. In the present study we determined whether these responses could be generalized to the leg. Based upon blood pressure differences between the leg and arm during upright posture, we hypothesized that the responsiveness to endothelium-dependent vasodilators would be greater in the forearm than the leg. @entity1503 (Q, ultrasound Doppler) at rest and during intra-arterial infusions of endothelium-dependent ( @entity934 and @entity4757 ) and -independent ( @entity1854 ) vasodilators were measured in eight healthy @entity1 (22-27 years old). Resting blood flows in the forearm before infusion of @entity934 , @entity4757 or @entity1854 were 25 +/- 4, 30 +/- 7 and 29 +/- 5 ml @entity1009 ), respectively, and in the leg were 370 +/- 32, 409 +/- 62 and 330 +/- 30 ml @entity1009 ), respectively. At the highest infusion rate of @entity934 (16 microg (100 ml tissue)(-1) @entity1009 )) there was a greater (P < 0.05) increase in Q to the forearm (1864 +/- 476%) than to the leg (569 +/- 86%). Similarly, at the highest infusion rate of @entity4757 (125 pg (100 ml tissue)(-1) @entity1009 )) there was a greater (P < 0.05) increase in Q to the forearm (911 +/- 286%) than to the leg (243 +/- 58%). The responses to @entity1854 (1 microg (100 ml tissue)(-1) @entity1009 )) were also greater (P < 0.05) in the forearm (925 +/- 164%) than in the leg (326 +/- 65%). These data indicate that vascular responses to both endothelium-dependent and -independent vasodilator agents are blunted in the leg compared to the forearm.

title: Different vasodilator responses of XXXX arms and legs.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human', 'men']

entities_list: @entity1854 :: ('MESH:D009599', 'Chemical') :: ['sodium nitroprusside']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['Brachial and femoral artery blood flow']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: Results of cisternal CSF analyses of 77 @entity235 with primary @entity1313 (1970 to 1984) were examined retrospectively. The types of primary @entity1313 were @entity816 , @entity2846 , @entity424 , @entity1653 , and @entity3271 . Fifty-three @entity235 had complete CSF analyses performed (total WBC count, total protein content, and pressure). Of these 53 CSF, 39.6% had a pattern of change consistent with current descriptions of CSF associated with @entity75 . Results of the remaining 60.4% of the 53 CSF were normal (9.4%) or had an atypical pattern of abnormality (50.9%). The CSF associated with @entity1653 was unique in having CSF with a WBC count greater than 50 cells/microliter and a WBC differential count greater than 50% @entity6415 ( @entity6415 ) cells. Within the @entity1653 group, a predominance of @entity6415 cells in the CSF correlated with @entity39 or @entity6415 cell infiltration of the @entity5 . Additional correlations between specific CSF characteristics and histologic features of the @entity5 could not be made. Statistical analysis of the 77 CSF revealed that the mean CSF total WBC count of the @entity3271 group was significantly less than the mean WBC count of the @entity2846 group and the @entity1653 group. The mean CSF total protein contents of the @entity816 group and the @entity1653 group were significantly less than the mean protein of the @entity2846 group. The mean CSF pressure of the @entity5 groups was not significantly different. For all 77 @entity5 , the most common abnormality was an increased total protein content (69.4%); the least common abnormality was an increased total WBC count (41.3%).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Characteristics of cisternal cerebrospinal fluid associated with primary XXXX in the @entity235 : a retrospective study.

entities_list: @entity6415 :: ('MESH:C566014', 'Disease') :: ['polymorphonuclear', 'PMN']

entities_list: @entity424 :: ('MESH:D004806', 'Disease') :: ['ependymomas']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumors']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brain neoplasia']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity1653 :: ('MESH:D008579', 'Disease') :: ['meningioma', 'meningiomas']

entities_list: @entity816 :: ('MESH:D001254', 'Disease') :: ['astrocytoma', 'astrocytomas']

entities_list: @entity2846 :: ('MESH:D020288', 'Disease') :: ['choroid plexus papilloma', 'choroid plexus papillomas']

entities_list: @entity3271 :: ('MESH:D009837', 'Disease') :: ['oligodendrogliomas', 'oligodendroglioma']

answer: @entity1313 :: (MESH:D001932,Disease) :: ['brain tumors']


abstract: Results of cisternal CSF analyses of 77 @entity235 with primary @entity1313 (1970 to 1984) were examined retrospectively. The types of primary @entity1313 were @entity816 , @entity2846 , @entity424 , @entity1653 , and @entity3271 . Fifty-three @entity235 had complete CSF analyses performed (total WBC count, total protein content, and pressure). Of these 53 CSF, 39.6% had a pattern of change consistent with current descriptions of CSF associated with @entity75 . Results of the remaining 60.4% of the 53 CSF were normal (9.4%) or had an atypical pattern of abnormality (50.9%). The CSF associated with @entity1653 was unique in having CSF with a WBC count greater than 50 cells/microliter and a WBC differential count greater than 50% @entity6415 ( @entity6415 ) cells. Within the @entity1653 group, a predominance of @entity6415 cells in the CSF correlated with @entity39 or @entity6415 cell infiltration of the @entity5 . Additional correlations between specific CSF characteristics and histologic features of the @entity5 could not be made. Statistical analysis of the 77 CSF revealed that the mean CSF total WBC count of the @entity3271 group was significantly less than the mean WBC count of the @entity2846 group and the @entity1653 group. The mean CSF total protein contents of the @entity816 group and the @entity1653 group were significantly less than the mean protein of the @entity2846 group. The mean CSF pressure of the @entity5 groups was not significantly different. For all 77 @entity5 , the most common abnormality was an increased total protein content (69.4%); the least common abnormality was an increased total WBC count (41.3%).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Characteristics of cisternal cerebrospinal fluid associated with primary @entity1313 in the XXXX : a retrospective study.

answer: @entity235 :: (9615,Species) :: ['dog']


abstract: PURPOSE: To evaluate initial experience with radiofrequency (RF) ablation of @entity4304 . MATERIALS AND METHODS: Thirteen adrenal masses in 12 @entity1 (bilateral @entity3 in one @entity1 ) were treated with computed tomography (CT)-guided percutaneous RF ablation. Eleven adrenal lesions were @entity3 (five from @entity2 , four from @entity1358 , and two from @entity320 ); one lesion was a @entity1911 and one was an aldosteronoma. There were 10 @entity1 and two @entity1 (average age, 58 years; range, 40-77 years) in the study; average adrenal mass diameter was 3.9 cm (range, 1-8 cm). Average number of RF applications per adrenal mass was 2.7 (range, 1-5 applications); average time per application was 7.8 minutes (range, 4-13 minutes). An internally cooled single electrode was used in five sessions; an internally cooled cluster electrode was used in eight sessions. RESULTS: Average follow-up was 11.2 months (range, 1-46 months). Eleven of 13 lesions were treated successfully with RF ablation after one session. Successful treatment was defined as lack of enhancement of the treated region on follow-up CT images and resolution of the biochemical abnormality in two @entity1 . In two @entity1 with large adrenal lesions (4 and 8 cm in diameter), enhancement of residual tissue was observed after one treatment session; this finding was indicative of @entity41 . One @entity1 with @entity882 that resulted from chemotherapy had a small @entity1410 , but no transfusion was required. No @entity1 developed @entity101 during the RF application. No @entity1 with @entity3 had recurrent @entity5 at the treated site, and this lack of recurrence indicated effective local control; 11 @entity1 had progression of @entity3 at extraadrenal sites. CONCLUSION: Preliminary data suggest that CT-guided RF ablation is an effective technique for local control of @entity4304 .

title: XXXX : CT-guided radiofrequency ablation--preliminary results.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor']

entities_list: @entity1911 :: ('MESH:D010673', 'Disease') :: ['pheochromocytoma']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'metastatic disease']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma']

entities_list: @entity4304 :: ('MESH:D000310', 'Disease') :: ['adrenal neoplasms']

answer: @entity4304 :: (MESH:D000310,Disease) :: ['Adrenal neoplasms']


abstract: OBJECTIVES: Our goal was to determine the incidental Lund score for pediatric @entity1 without @entity102 ( @entity102 ). METHODS: Pediatric @entity1 with computed tomography scans of the orbit or brain were identified. @entity1 with a clinical history of sinonasal disorders or skeletal facial @entity130 were excluded. The remaining scans were scored according to the Lund-MacKay system. Pneumatization of the frontal and sphenoid sinuses was also recorded. A scaled Lund score was computed, and the mean Lund score for this normal population was determined. RESULTS: One hundred ninety-two computed tomography scans were examined (mean age, 9.0 years). The frontal sinuses and sphenoid sinuses were absent in 40.1% and 1.6% of cases, respectively. The mean scaled Lund score in this pediatric population without @entity102 was 2.81 (95% confidence interval, 2.40 to 3.22). This result differed statistically from a score of 0 (P < 0.001). Only 37 (19.3%) @entity1 had completely radiographically normal sinuses. CONCLUSIONS: The mean incidental Lund score in the absence of @entity102 approaches 3, and this should be considered when determining the diagnostic likelihood of @entity102 in pediatric @entity1 .

title: Incidental paranasal sinus imaging abnormalities and the normal Lund score in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic rhinosinusitis', 'CRS']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: Heparin and heparin oligosaccharides prepared by @entity17241 depolymerization were fractionated by affinity chromatography on immobilized @entity5582 and by gel chromatography. The anticoagulant activities of high affinity heparin of Mr greater than or equal to 7,800 could be readily neutralized by the plasma protein @entity3793 -rich glycoprotein (see also Lijnen, H.R., Hoylaerts, M., and Collen, D. (1983) J. Biol. Chem. 258, 3803-3808), whereas oligosaccharides falling below 18 @entity1735 units (Mr 5,400) became increasingly resistant to neutralization. An @entity60641 with characteristic marked ability to accelerate the inactivation of @entity6236 by @entity5582 retained greater than 50% of its activity even at a @entity3793 -rich glycoprotein/oligosaccharide molar ratio of 500:1. @entity3793 -rich glycoprotein, like the platelet-derived heparin neutralizing protein platelet factor 4 (Lane, D.A., Denton, J., Flynn, A.M., Thunberg, L. and Lindahl, U. (1984) Biochem J. 218, 725-732), therefore requires interaction with @entity1735 sequences in addition to the @entity5582 -binding pentasaccharide of heparin in order to efficiently express its antiheparin activity. Heparan @entity597 isolated from @entity1707 intestinal mucosa ( @entity38796 , Mr approximately 20,000) and from @entity1 aorta (HS II, Mr approximately 40,000) exhibited anti- @entity6236 activities of 180 and 20 units/micromol [corrected], respectively. A fraction corresponding to about 5% of @entity38796 bound with high affinity to immobilized @entity5582 and contained all of the anticoagulant activity of the starting material. While these heparan @entity14024 were readily neutralized by platelet factor 4, they were relatively resistant to neutralization by @entity3793 -rich glycoprotein, although complete neutralization could be attained in the presence of molar excess of this protein. These findings may be of importance in relation (a) to the functional role of endogenous anticoagulant polysaccharides at the vascular wall and (b) to clinical situations in which heparin or heparin-related compounds are administered as exogenous anticoagulants.

title: Neutralization of heparin-related saccharides by XXXX -rich glycoprotein and platelet factor 4.

entities_list: @entity3793 :: ('CHEBI:27570', 'Chemical') :: ['Histidine', 'histidine']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['saccharide']

entities_list: @entity17241 :: ('MESH:D009608', 'Chemical') :: ['nitrous acid']

entities_list: @entity60641 :: ('CHEBI:61863', 'Chemical') :: ['octasaccharide']

entities_list: @entity597 :: ('CHEBI:16189', 'Chemical') :: ['sulfate']

answer: @entity3793 :: (CHEBI:27570,Chemical) :: ['histidine']


abstract: PURPOSE: Prior studies have reported @entity281 rates of converting non-tunneled dialysis catheters (NTDCs) to tunneled dialysis catheters (TDCs) versus de novo placement of TDCs using @entity4279 . @entity1216 , per the Center of Disease Control guidelines, has been exclusively used in our institution since 2005. Therefore, our study aims to determine whether there is a difference in @entity281 rates between conversion and de novo placement when utilizing @entity1216 . MATERIALS AND METHODS: A retrospective analysis from 1/1/2009 to 8/10/2012 was performed of @entity1 who underwent placement of NTDCs, which were subsequently converted to TDCs and those who underwent de novo TDC placement. To assess the rate of @entity281 , the following data points were collected: date of procedure(s), indication, outcomes, site of catheter insertion, pre- and post-procedure laboratory values, complications, @entity281 rates within the life of the initially placed catheter, catheter days, and survival. RESULTS: The conversion cohort was composed of 205 @entity1 , 135 of whom were lost to follow-up, leaving 70 @entity1 . The de novo cohort included 70 randomly selected @entity1 . Of the 70 @entity1 who underwent conversion, 23 developed a @entity1212 , with an @entity281 rate of 0.26 events per 100 catheter days. Of the 70 de novo catheters, 20 developed @entity281 with an @entity281 rate of 0.25 events per 100 catheters days. CONCLUSION: In this series, there is no difference in @entity281 rates between conversion and de novo TDC placement when utilizing @entity1216 as the sterilization agent. However, these @entity281 rates are superior to those reported when using @entity4279 .

title: Evaluation of XXXX rates in converted dialysis catheters versus de novo placement in the setting of @entity1216 use.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1216 :: ('MESH:D002710', 'Chemical') :: ['chlorhexidine', 'Chlorhexidine']

entities_list: @entity1212 :: ('MESH:D055499', 'Disease') :: ['catheter-related infection']

entities_list: @entity4279 :: ('MESH:D011206', 'Chemical') :: ['povidone-iodine']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity1212 :: (MESH:D055499,Disease) :: ['catheter infection']


abstract: PURPOSE: Prior studies have reported @entity281 rates of converting non-tunneled dialysis catheters (NTDCs) to tunneled dialysis catheters (TDCs) versus de novo placement of TDCs using @entity4279 . @entity1216 , per the Center of Disease Control guidelines, has been exclusively used in our institution since 2005. Therefore, our study aims to determine whether there is a difference in @entity281 rates between conversion and de novo placement when utilizing @entity1216 . MATERIALS AND METHODS: A retrospective analysis from 1/1/2009 to 8/10/2012 was performed of @entity1 who underwent placement of NTDCs, which were subsequently converted to TDCs and those who underwent de novo TDC placement. To assess the rate of @entity281 , the following data points were collected: date of procedure(s), indication, outcomes, site of catheter insertion, pre- and post-procedure laboratory values, complications, @entity281 rates within the life of the initially placed catheter, catheter days, and survival. RESULTS: The conversion cohort was composed of 205 @entity1 , 135 of whom were lost to follow-up, leaving 70 @entity1 . The de novo cohort included 70 randomly selected @entity1 . Of the 70 @entity1 who underwent conversion, 23 developed a @entity1212 , with an @entity281 rate of 0.26 events per 100 catheter days. Of the 70 de novo catheters, 20 developed @entity281 with an @entity281 rate of 0.25 events per 100 catheters days. CONCLUSION: In this series, there is no difference in @entity281 rates between conversion and de novo TDC placement when utilizing @entity1216 as the sterilization agent. However, these @entity281 rates are superior to those reported when using @entity4279 .

title: Evaluation of @entity1212 rates in converted dialysis catheters versus de novo placement in the setting of XXXX use.

answer: @entity1216 :: (MESH:D002710,Chemical) :: ['chlorhexidine']


abstract: UNASSIGNED: The medfly @entity19428 is one of the most important pests for horticulture worldwide. The knowledge about anatomy and function of the medfly olfactory system is still limited. The first brain structure to process olfactory information in insects is the @entity1315 ( @entity1315 ), which is composed of its functional and morphological units, the olfactory glomeruli. Here, we present a morphological three-dimensional reconstruction of @entity1315 glomeruli in adult brains. We used unilateral antennal backfills of olfactory receptor neurons (ORNs) with neural tracers, revealing the @entity1315 structure. We recorded confocal stacks acquired from whole-mount specimens, and analyzed them with the software AMIRA. The ALs in @entity19428 are organized in glomeruli which are more tightly packed in the anterior part than the posterior one. Axons of ORNs bilaterally connect the ALs through a commissure between the two ALs. This commissure is formed by several distinct fascicles. Contralateral dye transfer suggests the presence of gap junctions connecting ORNs from both antennae. There was no statistical difference between the average volumes of female ALs (204,166      12,554   m(3)) and of male ALs (190,287      11,823   m(3)). In most specimens, we counted 53 glomeruli in each @entity1315 , seven of which were sexually dimorphic in size.

title: Morphological characterization of the antennal lobes in the XXXX @entity19428 .

entities_list: @entity19428 :: ('7213', 'Species') :: ['Ceratitis capitata', 'C. capitata']

entities_list: @entity1315 :: ('MESH:D004833', 'Disease') :: ['AL', 'antennal lobe']

answer: @entity19428 :: (7213,Species) :: ['Mediterranean fruit fly']


abstract: UNASSIGNED: The medfly @entity19428 is one of the most important pests for horticulture worldwide. The knowledge about anatomy and function of the medfly olfactory system is still limited. The first brain structure to process olfactory information in insects is the @entity1315 ( @entity1315 ), which is composed of its functional and morphological units, the olfactory glomeruli. Here, we present a morphological three-dimensional reconstruction of @entity1315 glomeruli in adult brains. We used unilateral antennal backfills of olfactory receptor neurons (ORNs) with neural tracers, revealing the @entity1315 structure. We recorded confocal stacks acquired from whole-mount specimens, and analyzed them with the software AMIRA. The ALs in @entity19428 are organized in glomeruli which are more tightly packed in the anterior part than the posterior one. Axons of ORNs bilaterally connect the ALs through a commissure between the two ALs. This commissure is formed by several distinct fascicles. Contralateral dye transfer suggests the presence of gap junctions connecting ORNs from both antennae. There was no statistical difference between the average volumes of female ALs (204,166      12,554   m(3)) and of male ALs (190,287      11,823   m(3)). In most specimens, we counted 53 glomeruli in each @entity1315 , seven of which were sexually dimorphic in size.

title: Morphological characterization of the antennal lobes in the @entity19428 XXXX .

answer: @entity19428 :: (7213,Species) :: ['Ceratitis capitata']


abstract: A home measurement monitoring system has been developed for assessing progress and planning changes in care for @entity1 with @entity1577 . Daily diary recording of specified measurements, quantitative symptom data, and free text are to be used for early detection of deteriorating trends before serious complications develop. Daily measurements made at home are lung capacity, body weight, breathing rate, and pulse. The program has been in place for the past two years, and has maintained a 75-80% consistent diary response rate among the 111 @entity1 initially committed to the program. Measurements are easy to perform, equipment design is simple and rugged, and data handling routines designed for the program using the INSIGHT clinical data base system perform satisfactorily. Checking for data entry errors and validity checks of home measurements are a regular part of the data handling activity. @entity1 acceptance and long-term compliance in this program agrees very favorably with reports of other diary programs in @entity102 . Diary compliance was significantly greater among younger @entity1 and those who lived long distances from the hospital. This study has demonstrated that home monitoring is a feasible program for @entity1 with @entity1577 . It presents the possibility of detecting adverse health trends earlier than is now practical, so that @entity1 can be treated before serious complications develop, thereby preventing the large fluctuations in health status that often accompany @entity1577 .

title: Feasibility and compliance studies of a home measurement monitoring program for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient']

entities_list: @entity1577 :: ('MESH:D003550', 'Disease') :: ['CF', 'cystic fibrosis']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease']

answer: @entity1577 :: (MESH:D003550,Disease) :: ['cystic fibrosis']


abstract: UNASSIGNED: The present study aimed to assess the activity of @entity1358 ( @entity1358 ) containing bacteriocins on the formation and maintenance of biofilms developed by @entity5125 , and the associated effect of @entity5618 and @entity1098 ( @entity1098 ) on the formed biofilm. @entity1358 from 9 @entity880 bacteria (LAB) strains was tested for inhibitory activity against 85 @entity5125 isolates and 21 LAB strains. Then, 12 @entity5125 strains were selected based on genetic profiles and sensitivity to @entity1358 and were subjected to an in vitro assay to assess biofilm formation in microtiter plates, considering different culture media and incubation conditions. Based on these results, 6 @entity5125 strains were subjected to the same in vitro procedure to assess biofilm formation, being co-inoculated with @entity1358 . In addition, these strains were subjected to the same in vitro procedure, modified by adding the @entity1358 after biofilm formation. Relevant decrease in biofilm formation was observed in the first experiment, but @entity1358 added after biofilm formation did not eliminate them. @entity1358 from @entity20201 ET31 were selected due to its anti-biofilm activity, being associated to @entity1098 at different concentrations and tested for biofilm control of three strains of @entity5125 , using the same in vitro procedure described previously. Concentrated @entity5618 presented poor performance in eliminating formed biofilms, and @entity1098 concentration presented no evident interference on biofilm elimination. Twelve selected @entity5125 strains were positive for investigated virulence makers and negative for luxS gene, recognized as being involved in biofilm formation. Selected @entity5125 strains were able to produce biofilms under different conditions. CFSs have the potential to prevent biofilm formation, but they were not able to destroy already formed biofilms. Nevertheless, low concentrations of @entity1358 combined with @entity1098 caused a relevant reduction in already formed biofilms, but this association was not able to eliminate them. The activity of selected @entity1358 was demonstrated against @entity5125 -formed biofilms, being more effective when associated to @entity1098 at different concentrations.

title: In Vitro Evaluation of @entity5618 Activity Against XXXX Biofilm Formation.

entities_list: @entity5618 :: ('CHEBI:48081', 'Chemical') :: ['bacteriocins', 'bacteriocin']

entities_list: @entity5125 :: ('1639', 'Species') :: ['Listeria monocytogenes', 'L. monocytogenes']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['cell-free supernatant', 'CFS']

entities_list: @entity20201 :: ('28038', 'Species') :: ['Lactobacillus curvatus']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactic acid']

entities_list: @entity1098 :: ('MESH:D004492', 'Chemical') :: ['ethylene-diamine-tetra-acetic acid', 'EDTA']

answer: @entity5125 :: (1639,Species) :: ['Listeria monocytogenes']


abstract: UNASSIGNED: The present study aimed to assess the activity of @entity1358 ( @entity1358 ) containing bacteriocins on the formation and maintenance of biofilms developed by @entity5125 , and the associated effect of @entity5618 and @entity1098 ( @entity1098 ) on the formed biofilm. @entity1358 from 9 @entity880 bacteria (LAB) strains was tested for inhibitory activity against 85 @entity5125 isolates and 21 LAB strains. Then, 12 @entity5125 strains were selected based on genetic profiles and sensitivity to @entity1358 and were subjected to an in vitro assay to assess biofilm formation in microtiter plates, considering different culture media and incubation conditions. Based on these results, 6 @entity5125 strains were subjected to the same in vitro procedure to assess biofilm formation, being co-inoculated with @entity1358 . In addition, these strains were subjected to the same in vitro procedure, modified by adding the @entity1358 after biofilm formation. Relevant decrease in biofilm formation was observed in the first experiment, but @entity1358 added after biofilm formation did not eliminate them. @entity1358 from @entity20201 ET31 were selected due to its anti-biofilm activity, being associated to @entity1098 at different concentrations and tested for biofilm control of three strains of @entity5125 , using the same in vitro procedure described previously. Concentrated @entity5618 presented poor performance in eliminating formed biofilms, and @entity1098 concentration presented no evident interference on biofilm elimination. Twelve selected @entity5125 strains were positive for investigated virulence makers and negative for luxS gene, recognized as being involved in biofilm formation. Selected @entity5125 strains were able to produce biofilms under different conditions. CFSs have the potential to prevent biofilm formation, but they were not able to destroy already formed biofilms. Nevertheless, low concentrations of @entity1358 combined with @entity1098 caused a relevant reduction in already formed biofilms, but this association was not able to eliminate them. The activity of selected @entity1358 was demonstrated against @entity5125 -formed biofilms, being more effective when associated to @entity1098 at different concentrations.

title: In Vitro Evaluation of XXXX Activity Against @entity5125 Biofilm Formation.

answer: @entity5618 :: (CHEBI:48081,Chemical) :: ['Bacteriocins']


abstract: Thallium-201 single photon emission computed tomography (SPECT) is a new method for the scintigraphic visualization of the left ventricular myocardium. With SPECT a three-dimensional imaging by computerized slicing of the myocardium in various axes is possible. To investigate the capabilities of this new imaging technique, detection and quantification of remote transmural @entity1188 were compared with ventriculographic, coronarographic and electrocardiographic findings. 31 of 80 investigated @entity1 had had a prior @entity583 . The left ventricular myocardium was divided into 7 regions in the scintigraphic as well as in the angiographic studies. In a total of 560 segments the sensitivity of SPECT for @entity1188 detection was 87.5% with a specificity of 99.8%. @entity1188 which were not detected scintigraphically were relatively small (mean 13.5% of the circumference). To quantify the @entity1188 , the size of the defect was determined scintigraphically from a sagittal long axis and two short axes, and the images compared with angiographic @entity1188 sizes (% of the circumference) according to the method of Feild et al. A good correlation without overestimation of the size by one method (SPECT defect = 0.93 X ventriculographic defect - 1.2%; r = 0.7, p less than 0.001) was obtained. Also a good separation of the perfusion areas of the coronary arteries due to the three-dimensional imaging with SPECT was possible. Thus, by employing Thallium-201 SPECT of the left ventricular myocardium exact localization and quantification of transmural @entity583 with a positive predictive value of 98% can be achieved.

title: [Detection, quantification and localization of XXXX : comparison of thallium single photon emission computer tomography with biplane angiography].

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'myocardial infarcts']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarctions', 'infarct', 'Infarcts']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarcts']


abstract: PURPOSE: Infusion of @entity1722 -specific T cells, derived from vaccine-primed @entity1 and expanded with @entity1199 /IL12, has induced @entity5 regression in a minority of @entity1 with metastatic treatment-refractory @entity1722 (+) @entity0 . We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL DESIGN: Using the TgMMTV-neu @entity19 @entity5 model, we cultured T cells derived from @entity19 immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion. RESULTS: Infusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused na  ve splenocytes (P < 0.05). T cells cultured with @entity1199 / @entity15787 could uniquely mediate complete regression of spontaneous @entity5 . @entity1199 / @entity15787 cultured neu-specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of @entity310 and @entity4155 (P < 0.05). Moreover, @entity5 -infiltrating @entity405 (+) cells were significantly increased after the infusion of @entity1199 / @entity15787 cultured T cells as compared with @entity5 treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of @entity1199 / @entity15787 cultured cells was mediated by @entity405 T cells. Depletion of @entity310 or @entity4155 , but not IFNy, abrogated the @entity5 growth inhibition induced by the @entity1199 / @entity15787 T cells and markedly decreased the influx of @entity405 into @entity5 . Finally, @entity1199 / @entity15787 -cultured human antigen specific T cells also displayed a similar polyfunctional @entity1198 /Th17 phenotype. CONCLUSIONS: Expansion of @entity1722 vaccine-primed T cells with @entity1199 / @entity15787 may have the potential to effectively mediate @entity5 regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16.   2015 AACR.

title: The Antitumor Efficacy of XXXX / @entity15787 -Cultured Polyfunctional Neu-Specific T Cells Is @entity310 / @entity4155 Dependent.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'mammary tumors', 'mammary tumor', 'tumors']

answer: @entity1199 :: (3558,Gene) :: ['IL2']


abstract: PURPOSE: Infusion of @entity1722 -specific T cells, derived from vaccine-primed @entity1 and expanded with @entity1199 /IL12, has induced @entity5 regression in a minority of @entity1 with metastatic treatment-refractory @entity1722 (+) @entity0 . We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL DESIGN: Using the TgMMTV-neu @entity19 @entity5 model, we cultured T cells derived from @entity19 immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion. RESULTS: Infusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused na  ve splenocytes (P < 0.05). T cells cultured with @entity1199 / @entity15787 could uniquely mediate complete regression of spontaneous @entity5 . @entity1199 / @entity15787 cultured neu-specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of @entity310 and @entity4155 (P < 0.05). Moreover, @entity5 -infiltrating @entity405 (+) cells were significantly increased after the infusion of @entity1199 / @entity15787 cultured T cells as compared with @entity5 treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of @entity1199 / @entity15787 cultured cells was mediated by @entity405 T cells. Depletion of @entity310 or @entity4155 , but not IFNy, abrogated the @entity5 growth inhibition induced by the @entity1199 / @entity15787 T cells and markedly decreased the influx of @entity405 into @entity5 . Finally, @entity1199 / @entity15787 -cultured human antigen specific T cells also displayed a similar polyfunctional @entity1198 /Th17 phenotype. CONCLUSIONS: Expansion of @entity1722 vaccine-primed T cells with @entity1199 / @entity15787 may have the potential to effectively mediate @entity5 regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16.   2015 AACR.

title: The Antitumor Efficacy of @entity1199 / XXXX -Cultured Polyfunctional Neu-Specific T Cells Is @entity310 / @entity4155 Dependent.

answer: @entity15787 :: (59067,Gene) :: ['IL21']


abstract: PURPOSE: Infusion of @entity1722 -specific T cells, derived from vaccine-primed @entity1 and expanded with @entity1199 /IL12, has induced @entity5 regression in a minority of @entity1 with metastatic treatment-refractory @entity1722 (+) @entity0 . We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL DESIGN: Using the TgMMTV-neu @entity19 @entity5 model, we cultured T cells derived from @entity19 immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion. RESULTS: Infusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused na  ve splenocytes (P < 0.05). T cells cultured with @entity1199 / @entity15787 could uniquely mediate complete regression of spontaneous @entity5 . @entity1199 / @entity15787 cultured neu-specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of @entity310 and @entity4155 (P < 0.05). Moreover, @entity5 -infiltrating @entity405 (+) cells were significantly increased after the infusion of @entity1199 / @entity15787 cultured T cells as compared with @entity5 treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of @entity1199 / @entity15787 cultured cells was mediated by @entity405 T cells. Depletion of @entity310 or @entity4155 , but not IFNy, abrogated the @entity5 growth inhibition induced by the @entity1199 / @entity15787 T cells and markedly decreased the influx of @entity405 into @entity5 . Finally, @entity1199 / @entity15787 -cultured human antigen specific T cells also displayed a similar polyfunctional @entity1198 /Th17 phenotype. CONCLUSIONS: Expansion of @entity1722 vaccine-primed T cells with @entity1199 / @entity15787 may have the potential to effectively mediate @entity5 regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16.   2015 AACR.

title: The Antitumor Efficacy of @entity1199 / @entity15787 -Cultured Polyfunctional Neu-Specific T Cells Is @entity310 / XXXX Dependent.

answer: @entity4155 :: (3605,Gene) :: ['IL17']


abstract: PURPOSE: Infusion of @entity1722 -specific T cells, derived from vaccine-primed @entity1 and expanded with @entity1199 /IL12, has induced @entity5 regression in a minority of @entity1 with metastatic treatment-refractory @entity1722 (+) @entity0 . We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL DESIGN: Using the TgMMTV-neu @entity19 @entity5 model, we cultured T cells derived from @entity19 immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion. RESULTS: Infusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused na  ve splenocytes (P < 0.05). T cells cultured with @entity1199 / @entity15787 could uniquely mediate complete regression of spontaneous @entity5 . @entity1199 / @entity15787 cultured neu-specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of @entity310 and @entity4155 (P < 0.05). Moreover, @entity5 -infiltrating @entity405 (+) cells were significantly increased after the infusion of @entity1199 / @entity15787 cultured T cells as compared with @entity5 treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of @entity1199 / @entity15787 cultured cells was mediated by @entity405 T cells. Depletion of @entity310 or @entity4155 , but not IFNy, abrogated the @entity5 growth inhibition induced by the @entity1199 / @entity15787 T cells and markedly decreased the influx of @entity405 into @entity5 . Finally, @entity1199 / @entity15787 -cultured human antigen specific T cells also displayed a similar polyfunctional @entity1198 /Th17 phenotype. CONCLUSIONS: Expansion of @entity1722 vaccine-primed T cells with @entity1199 / @entity15787 may have the potential to effectively mediate @entity5 regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16.   2015 AACR.

title: The Antitumor Efficacy of @entity1199 / @entity15787 -Cultured Polyfunctional Neu-Specific T Cells Is XXXX / @entity4155 Dependent.

answer: @entity310 :: (7124,Gene) :: ['TNFa']


abstract: BACKGROUND _ AIMS: Optimal nutritional care for intensive care unit (ICU) @entity1 requires precise determination of @entity7493 ( @entity7493 ) to avoid deleterious under- or overfeeding. The reference method, @entity4629 ( @entity4629 ), is rarely accessible and inconstantly feasible. Various equations for predicting @entity7493 based on body weight (BW) are available. This study aims at determining the best prediction strategy unless @entity4629 is available. METHODS: Mechanically ventilated @entity1 staying >= 72  h in the ICU were included, except those with contraindications for @entity4629 measurements. @entity4629 and BW measurements were routinely performed. @entity7493 was predicted by the ESPEN formula and other predictive equations using BW (i.e. anamnestic (AN), measured (MES), adjusted for cumulated water balance (ADJ), calculated for a body mass index (BMI) of 22.5). Comparisons were made using Pearson correlation and Bland _ Altman plots. RESULTS: 85 @entity1 (57      19  y, 61 @entity1 , SAPS II 43      16) were included. Correlations between @entity4629 and predicted @entity7493 using the ESPEN formula with different BW (BWAN, BWMES, BWADJ, and BWBMI22.5) were 0.44, 0.40, 0.36, and 0.47, respectively. Bland _ Altman plots showed wide and inconsistent variations. Predictive equations including body temperature and minute ventilation showed the best correlations, but when using various BWs, differences in predicted @entity7493 were observed. CONCLUSION: No @entity7493 predictive equation, regardless of the BW used, gives statistically identical results to @entity4629 . If @entity4629 cannot be performed, predictive equations including minute ventilation and body temperature should be preferred. BW has a significant impact on estimated @entity7493 and the use of measured BWMES or BW BMI 22.5 is associated with the best @entity7493 prediction. Clinical trial registration number on ClinicalTrial.gov: NCT02552446. Ethical committee number: CE-14-070.

title: Energy expenditure in mechanically ventilated XXXX : The weight of body weight!

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity7493 :: ('MESH:D011502', 'Disease') :: ['energy expenditure', 'EE']

entities_list: @entity4629 :: ('MESH:D051556', 'Disease') :: ['indirect calorimetry', 'IC']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: Purpose To evaluate the association of @entity456 with visceral @entity3 of @entity1149 ( @entity1149 ) that does not abut the pleural surface. Materials and Methods This retrospective study was approved by the institutional review board. Informed consent was waived. The study of @entity1149 that does not abut the pleura in 141 @entity1 (44 @entity1 [31.2%] with visceral @entity3 proved by pathologic analysis and 97 @entity1 [68.8%] without @entity3 ) was conducted at a single tertiary center. The @entity456 were classified into three types (type 1, one or more linear @entity456 ; type 2, one or more linear @entity456 with soft tissue component at the pleural end; and type 3, one or more soft tissue cord-like @entity456 ) and prioritized into types 3, 2, and 1 when more than one type was present. Diagnostic accuracy, sensitivity, specificity, positive predictive value ( @entity2286 ), negative predictive value (NPV), and positive likelihood ratio (LR) were calculated. Results In the absence of @entity456 , no @entity3 was found. The presence of type 2 @entity456 was moderately associated with visceral @entity3 with the following results: positive LR, 5.06; accuracy, 71%; sensitivity, 36.4%; specificity, 92.8%; @entity2286 , 76.2%; and NPV, 69.6%. Type 1 @entity456 provided weak evidence to rule out visceral @entity3 (positive LR, 0.38). Type 3 @entity456 indicated minimal increase in the likelihood of visceral @entity3 (positive LR, 1.68). Conclusion Type 2 @entity456 on conventional CT images can increase the accuracy of early diagnosis of visceral @entity3 by @entity1149 that does not abut the pleura. (  ) RSNA, 2015.

title: Pleural Tags on CT Scans to Predict Visceral Pleural Invasion of XXXX That Does Not Abut the Pleura.

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['pleural invasion']

entities_list: @entity456 :: ('MESH:D010995', 'Disease') :: ['pleural tag', 'pleural tags']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['Non-Small Cell Lung Cancer']


abstract: PURPOSE: To compare the objective and subjective quality of vision after femtosecond laser-assisted small incision lenticule extraction (SMILE) and laser-assisted subepithelial keratomileusis (LASEK) for mild to moderate @entity1714 . METHODS: This prospective, comparative study included 65 eyes of 33 @entity1 in the SMILE group, with a mean spherical equivalent (SE) of -4.16    0.82 diopters, and 50 eyes of 25 @entity1 in the LASEK group, with a mean SE of -3.81    0.97 diopters. Visual acuity, corneal topography, contrast sensitivity, and wavefront aberrations were recorded preoperatively and compared with postoperative measurements. A quality of vision questionnaire was scored and analyzed 3 months postoperatively. RESULTS: Three months postoperatively, the SMILE group had fewer (P < .05) higher-order aberrations (HOAs) (0.390    0.175   m), including spherical aberration (SA) (0.262    0.242   m), than the LASEK group (HOAs = 0.479    0.148   m, SA = 0.576    0.287   m, trefoil = 0.465    0.248   m). There was no significant difference in the amount of @entity772 and trefoil between the two groups after surgery. Analysis of the scores of glare and halos in the quality of vision questionnaire revealed that SMILE (night glare = 1.25    1.22, halos = 0.97    1.12) provided a better quality of vision (P < .05) than LASEK (night glare = 2.32    1.99, halos = 1.96    1.77). The two groups demonstrated no significant difference in contrast sensitivity 3 months postoperatively. No vision-threatening complications were noted at any stage in either group. CONCLUSIONS: Both SMILE and LASEK are safe and effective surgical procedures in the correction of @entity1714 . SMILE has a lower induction rate of HOAs and a higher degree of @entity1 satisfaction than LASEK at 3 months postoperatively. [J Refract Surg. 2015;31(12):795-800.].

title: Comparison of Visual Quality After SMILE and LASEK for Mild to Moderate XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

answer: @entity1714 :: (MESH:D009216,Disease) :: ['Myopia']


abstract: UNASSIGNED: Protein drugs are currently delivered by bolus injection and although treatment frequently is successful, these methods also have major drawbacks, which call for the development of alternative technologies allowing prolonged delivery of these drugs. We developed a new ex vivo gene therapy platform called Transduced Autologous Restorative Gene Therapy (TARGT) for sustained long term production and secretion of autologous therapeutic proteins. A biopsy of dermal tissue taken from the @entity1 is transduced ex vivo with a viral vector encoding the required gene under a constitutive promoter. Following measurement of protein secretion ex vivo, the transduced dermal tissue is implanted back into the @entity1 , where it secretes the therapeutic protein into the circulation for several months or longer. A major hurdle to this approach is potential immunogenicity of the transduced tissue following implantation. In this paper we describe the preclinical and early clinical development of this technology, which allowed overcoming these hurdles. To that end, we have used the @entity734 ( @entity734 ) adenoviral vector with newly designed expression cassette containing genetic elements to optimize transgene expression. Moreover, we have developed procedures for TARGT tissue implantation, with measures to improve engraftment and reduce @entity32 and rejection. Implantation of @entity1 TARGT to immune-deficient @entity915 @entity19 indicated long-term production of active proteins in the blood. Preliminary results of a clinical trial from two @entity454 @entity1 , implanted with TARGTs expressing the @entity1 @entity1307 ( @entity1307 ) gene, demonstrated prolonged secretion with physiologic blood level of the hormone and Hemoglobin maintenance in the desired range, for a period of at least five months without exogenous @entity1307 administration. We believe that the TARGT technology has the potential to become a platform for the sustained delivery of therapeutic proteins in various clinical indications.

title: Preclinical and preliminary clinical evaluation of genetically transduced dermal tissue implants for the sustained secretion of XXXX and interferon a.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'patient']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1307 :: ('2056', 'Gene') :: ['erythropoietin', 'EPO']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['helper dependent', 'HD']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['anemic end-stage renal disease']

answer: @entity1307 :: (2056,Gene) :: ['erythropoietin']